Abstract Details

Title Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Mohammed Bari PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Scott Siegert	Mr. Siegert has received personal compensation for serving as an employee of Neurocrine Biosciences. Mr. Siegert has stock in Neurocrine Biosciences.
Christopher F. O'Brien, MD, FAAN	No disclosure on file

��ɫ����